Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
30-day single-arm study of rivaroxaban (Xarelto) in children with venous thrombosis
2011-004539-30Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in Phlebothrombosis and venous thromboembolism (VTE), sponsored by Bayer. Primary endpoints: Safety of rivaroxaban in pediatric venous thrombosis, Efficacy of rivaroxaban in pediatric venous thrombosis and 1 more. Started Aug 2012; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Phlebothrombosisvenous thromboembolism (VTE)
Beyond the preview
Go deeper on 2011-004539-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004539-30.